knowledge -WSS

knowledge

author：fashion 2025-08-23 08:56:32 - browse：6358

Has PhRMA lost its fangs? Are 11th-hour changes ominous for clinical trials? And what’s next in pain medicine?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. The pharmaceutical industry, in court and in Congress, is working to water down legislation that will let Medicare negotiate certain drug prices. STAT Washington correspondent Rachel Cohrs joins us to explain the industry’s struggle to make headway — and how it factors into the 2024 election. We also discuss the latest news in the life sciences, including a twist in the future of Alnylam Pharmaceuticals, competition to Vertex Pharmaceuticals’ pain drug, and Gilead Sciences’ latest acquisition.

For more on what we cover, here’s all of Rachel’s coverage; here’s more on Vertex’s competition; here’s the news on Gilead; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Drug repurposing or repositioning? The language matters
Next article： Physicians and social media: If you see something, say something?

hotspot

WSS

Cholera vaccine supply gets boost as demand surges globally

Health AI adoption puts security, privacy startups on investors' radar

Baby aspirin cuts fat buildup in liver disease patients, in small study

Colonoscopy prep: Liquid

Health care needs a new profession: neuroimaging counseling

Future doctors should be trained to promote social change

hotspot

knowledge

knowledge

ChatGPT in medicine: STAT answers readers' burning questions

Orangutan used medicinal plant to treat wound, first time ever seen

BioMarin wins approval for gene therapy to treat hemophilia A

Orchard's therapy for neuron disease in children wins FDA approval

New air purifier tech could be key to improving indoor air quality

App could help diagnose ear infections more accurately — and at home

Affirmative action in medical school literally saved lives

Leading voice in opioid treatment defends methadone clinic system

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

After traumatic brain injury, life support decisions can use more time

entertainment

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Melinda French Gates resigns from Gates Foundation

Cell therapy fails to slow type 1 diabetes, but safety is established

MultiPlan and major insurers sued for alleged medical price

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Wikipedia

hotspot

focus

focus